查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球主动植入医疗器材市场 -2023-2030
市场调查报告书
商品编码
1373372

全球主动植入医疗器材市场 -2023-2030

Global Active Implantable Medical Devices Market -2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

主动式植入式医疗器械是指为了诊断或治疗目的而全部或部分引入人体的主动医疗器械。主动植入式医疗设备包括多种设备，包括心律调节器、除颤器、输液帮浦、心室辅助系统和设备、人工耳蜗和神经刺激器。

有源植入式医疗设备旨在长时间与身体直接接触，并遵守严格的标准和要求，以保护患者的健康和安全。有源植入式医疗设备也广泛应用于心血管、神经病学和骨科等各种领域。

市场动态

增加设备发布

主动式植入式医疗器材产品的推出数量不断增加，成为市场成长的重要推手。此外，许多主要参与者透过推出新的治疗设备在市场的进步中发挥重要作用。

例如，2023 年 5 月，微创 CRM 的最新系列植入式心律调节器 AlizeaTM 和 CeleaTM 获得美国 FDA 批准。这些是现代起搏器技术，在皮肤下体积小且离散，更容易植入。

此外，2022年12月，美敦力推出了一款名为Percept PC的深部脑植入式刺激器，配备了名为BrainSense的技术，可为帕金森氏症等神经系统疾病患者提供电深部脑部刺激（DBS ）治疗。

此外，2022 年 8 月，美敦力 (Medtronic) 公司。推出血管外植入式心律转復除颤器 (EV ICD) 系统去颤器，导线置于胸骨下方。

此外，慢性病盛行率和发病率上升以及使用主动植入医疗设备进行微创手术的日益普及等重要成长动力预计将在预测期内推动市场发展。

与植入式起搏器相关的併发症

与植入心律调节器相关的併发症将阻碍预测期内的市场成长。根据梅奥诊所的说法，起搏器部位可能会出现肿胀、出血或瘀伤，尤其是在患者服用血液稀释剂的情况下。它也可能导致起搏器部位附近的血栓栓塞（血块）或起搏器附近的血管或神经损伤。

目录

第 1 章：方法与范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

  • 按设备类型分類的片段
  • 按应用程式片段
  • 最终用户摘录
  • 按地区分類的片段

第 4 章：市场动态

  • 影响因素
    • 司机
      • 增加设备发布
      • YY
    • 限制
      • 与植入式起搏器相关的併发症
      • YY
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • DMI 意见

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆发前的情景
    • 新冠疫情期间的情景
    • 新冠疫情后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商策略倡议
  • 结论

第 7 章：按装置类型

  • 植入式心臟復律去颤器
    • 经静脉植入式心臟復律去颤器
      • 双心室植入式心臟復律去颤器
      • 双腔植入式心臟復律去颤器
      • 单腔植入式心臟復律去颤器
    • 皮下植入式心臟復律去颤器
  • 植入式心臟节律器
  • 心室辅助装置
  • 神经刺激器
  • 植入式听力设备
  • 植入式心臟监测仪
  • 植入式血糖监测仪

第 8 章：按应用

  • 心血管
  • 神经病学
  • 骨科
  • 其他的

第 9 章：最终用户

  • 医院
  • 门诊手术中心
  • 心臟中心
  • 神经中心
  • 其他的

第 10 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 12 章：公司简介

  • Boston Scientific Corporation
    • 公司简介
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Medtronic Plc
  • MED-EL
  • Nurotron Biotechnology Co. Ltd.
  • Abbott Laboratories
  • Cochlear Ltd
  • Sanova Holding AG
  • LivaNova Plc
  • Biotronik Inc.
  • Osypka Medical

第 13 章：附录

简介目录
Product Code: MD1510

Overview

An active implantable medical device is an active medical device intended to be totally or partially introduced into the human body for diagnostic or therapeutic purposes. An active implantable medical device includes a wide range of devices, including pacemakers, defibrillators, infusion pumps, ventricular assist systems and devices, cochlear implants, and neurostimulators.

Active implantable medical devices are designed to remain in direct contact with the body for extended periods and they are subject to rigorous standards and requirements to protect the health and safety of patients. Active implantable medical devices are also widely used in various applications such as in the cardiovascular, neurology, and orthopedic.

Market Dynamics

Increasing device launches

The increasing number of product launches for active implantable medical devices acts as a significant driver for market growth. Also, many key players play a major role in the advancements of the market by launching new treatment devices.

For instance, in May 2023, MicroPort CRM received U.S. FDA approval for its latest range of implantable pacemakers, AlizeaTM and CeleaTM. These are modern pacemaker technology that is small and discrete under the skin, making it easier to implant.

Also, in December 2022, Medtronic launched a deep brain implantable stimulator called Percept PC which is equipped with technology called BrainSense to provide electrical deep brain stimulation (DBS) treatment to patients with neurological diseases such as Parkinson's disease.

Additionally, in August 2022, Medtronic plc. Launched an extravascular implantable cardioverter defibrillator (EV ICD) system defibrillator with a lead put under the breastbone.

Furthermore, significant growth drivers such as the rising prevalence and incidence of chronic diseases, and the growing adoption of minimally invasive surgeries by using active implantable medical devices are expected to drive the market in the forecast period.

Complications related to implantable pacemakers

The complications related to implanted pacemakers will hamper the market growth in the forecast period. As per the Mayo Clinic, swelling, bleeding, or bruising can occur at the pacemaker site, particularly if the patient is taking blood thinners. It can also cause thromboembolism (blood clots) near the pacemaker site or the blood vessel or nerve damage near the pacemaker.

Segment Analysis

The global active implantable medical devices market is segmented based on device type, application, end users, and region.

Neurostimulators accounted for approximately 47.3% of the market share

An implantable neurostimulator delivers mild electrical signals to the epidural space near the spine through thin wires called leads. Neurostimulators are expected to hold the largest market share over the period forecast owing to increasing new neurostimulator launches and technical advancements.

For instance, in April 2023, Synapse Biomedical, Inc. launched the NeuRx Diaphragm Pacing System which is a battery-powered device that delivers electrical stimulation via four percutaneous intramuscular electrodes implanted into the diaphragm with minimally invasive laparoscopy.

Additionally, in December 2022, Abbott launched the Eterna spinal cord stimulation (SCS) system which is the smallest implantable, rechargeable spinal cord stimulator for the treatment of chronic pain.

Geographical Analysis

North America is expected to hold a significant position in the global active implantable medical devices market share

The global active implantable medical devices market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

North America has maintained a significant market proportion due to factors such as the rising prevalence of atrial fibrillation, and increasing adoption of cardiac pacemaker implantation, this trend is anticipated to continue throughout the forecast period.

For instance, according to the National Institute of Health 2022, it is estimated that in the United States, the number of people with an implantable pacemaker is between 500,000 and 3 million. The chance of pacemaker implantation increases with age for over 70% of all pacemakers that are implanted in patients over the age of 65.

Additionally, according to Healthline Media, it is estimated that the prevalence of atrial fibrillation in the United States ranges from about 2.7 million to 6.1 million. It is estimated to rise to 12.1 million in 2030. Hence, due to the increasing number of people with atrial fibrillation, the rate of pacemaker implantation is expected to increase to treat heart diseases.

COVID-19 Impact Analysis:

The COVID-19 pandemic has had a significant impact on the global active implantable medical devices market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatments, device launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the active implantable medical devices market is expected to be moderately affected over the forecast period.

Competitive Landscape

The major global players in the market include: Boston Scientific Corporation, Medtronic Plc, MED-EL, Nurotron Biotechnology Co. Ltd., Abbott Laboratories, Cochlear Ltd, Sanova Holding AG, LivaNova Plc, Biotronik Inc., Osypka Medical among others.

Key Developments

  • In June 2023, Medics invested £1.8 million for clinical trials with the aim of precisely targeting heart patients who need tiny defibrillators to be fitted under their skin with the aim of reducing deaths from sudden cardiac arrests.
  • In June 2021, India Medtronic Private Limited launched Micra AV, a little, a fully self-contained pacemaker that uses a minimally invasive method to provide sophisticated pacing technology to those with atrioventricular (AV) block.

Why Purchase the Report?

  • To visualize the global active implantable medical devices market segmentation based on device type, application, end users and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of active implantable medical devices market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global active implantable medical devices market report would provide approximately 61 tables, 62 figures, and 185 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Device Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End Users
  • 3.4. Snippet by Region

4. Market Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing device launches
      • 4.1.1.2.
    • 4.1.2. Restraints
      • 4.1.2.1. Complications related to implantable pacemakers
      • 4.1.2.2.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Device Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 7.1.2. Market Attractiveness Index, By Device Type
  • 7.2. Implantable Cardioverter Defibrillators*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Transvenous Implantable Cardioverter Defibrillators
      • 7.2.3.1. Biventricular Implantable Cardioverter Defibrillators
      • 7.2.3.2. Dual-Chamber Implantable Cardioverter Defibrillators
      • 7.2.3.3. Single-Chamber Implantable Cardioverter Defibrillators
    • 7.2.4. Subcutaneous Implantable Cardioverter Defibrillators
  • 7.3. Implantable Cardiac Pacemakers
  • 7.4. Ventricular Assist Devices
  • 7.5. Neurostimulators
  • 7.6. Implantable Hearing Devices
  • 7.7. Implantable Heart Monitors
  • 7.8. Implantable Glucose Monitors

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cardiovascular*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Neurology
  • 8.4. Orthopedic
  • 8.5. Others

9. By End Users

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 9.1.2. Market Attractiveness Index, By End Users
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Cardiac Centers
  • 9.5. Neuro Centers
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Boston Scientific Corporation
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Medtronic Plc
  • 12.3. MED-EL
  • 12.4. Nurotron Biotechnology Co. Ltd.
  • 12.5. Abbott Laboratories
  • 12.6. Cochlear Ltd
  • 12.7. Sanova Holding AG
  • 12.8. LivaNova Plc
  • 12.9. Biotronik Inc.
  • 12.10. Osypka Medical

LIST NOT EXHAUSTIVE.

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us